Cell Reports (Nov 2019)

Genomic Profiling of Childhood Tumor Patient-Derived Xenograft Models to Enable Rational Clinical Trial Design

  • Jo Lynne Rokita,
  • Komal S. Rathi,
  • Maria F. Cardenas,
  • Kristen A. Upton,
  • Joy Jayaseelan,
  • Katherine L. Cross,
  • Jacob Pfeil,
  • Laura E. Egolf,
  • Gregory P. Way,
  • Alvin Farrel,
  • Nathan M. Kendsersky,
  • Khushbu Patel,
  • Krutika S. Gaonkar,
  • Apexa Modi,
  • Esther R. Berko,
  • Gonzalo Lopez,
  • Zalman Vaksman,
  • Chelsea Mayoh,
  • Jonas Nance,
  • Kristyn McCoy,
  • Michelle Haber,
  • Kathryn Evans,
  • Hannah McCalmont,
  • Katerina Bendak,
  • Julia W. Böhm,
  • Glenn M. Marshall,
  • Vanessa Tyrrell,
  • Karthik Kalletla,
  • Frank K. Braun,
  • Lin Qi,
  • Yunchen Du,
  • Huiyuan Zhang,
  • Holly B. Lindsay,
  • Sibo Zhao,
  • Jack Shu,
  • Patricia Baxter,
  • Christopher Morton,
  • Dias Kurmashev,
  • Siyuan Zheng,
  • Yidong Chen,
  • Jay Bowen,
  • Anthony C. Bryan,
  • Kristen M. Leraas,
  • Sara E. Coppens,
  • HarshaVardhan Doddapaneni,
  • Zeineen Momin,
  • Wendong Zhang,
  • Gregory I. Sacks,
  • Lori S. Hart,
  • Kateryna Krytska,
  • Yael P. Mosse,
  • Gregory J. Gatto,
  • Yolanda Sanchez,
  • Casey S. Greene,
  • Sharon J. Diskin,
  • Olena Morozova Vaske,
  • David Haussler,
  • Julie M. Gastier-Foster,
  • E. Anders Kolb,
  • Richard Gorlick,
  • Xiao-Nan Li,
  • C. Patrick Reynolds,
  • Raushan T. Kurmasheva,
  • Peter J. Houghton,
  • Malcolm A. Smith,
  • Richard B. Lock,
  • Pichai Raman,
  • David A. Wheeler,
  • John M. Maris

Journal volume & issue
Vol. 29, no. 6
pp. 1675 – 1689.e9

Abstract

Read online

Summary: Accelerating cures for children with cancer remains an immediate challenge as a result of extensive oncogenic heterogeneity between and within histologies, distinct molecular mechanisms evolving between diagnosis and relapsed disease, and limited therapeutic options. To systematically prioritize and rationally test novel agents in preclinical murine models, researchers within the Pediatric Preclinical Testing Consortium are continuously developing patient-derived xenografts (PDXs)—many of which are refractory to current standard-of-care treatments—from high-risk childhood cancers. Here, we genomically characterize 261 PDX models from 37 unique pediatric cancers; demonstrate faithful recapitulation of histologies and subtypes; and refine our understanding of relapsed disease. In addition, we use expression signatures to classify tumors for TP53 and NF1 pathway inactivation. We anticipate that these data will serve as a resource for pediatric oncology drug development and will guide rational clinical trial design for children with cancer. : Rokita et. al provide an extensively annotated genomic dataset of somatic oncogenic regulation across 37 distinct pediatric malignancies. The 261 patient-derived xenograft models are available to the scientific community, and the genomic annotations will enable rational preclinical agent prioritization and acceleration of therapeutic targets for early-phase pediatric oncology clinical trials. Keywords: pediatric cancer, patient-derived xenograft, relapse, whole-exome sequencing, transcriptome sequencing, copy number profiling, preclinical testing, classifier